What is a brief summary of the differences between active and non‑active (stable) disease in multiple sclerosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Active vs. Non-Active Multiple Sclerosis: Key Distinctions

Active disease in MS is defined by the presence of clinical relapses and/or MRI evidence of new inflammatory activity (gadolinium-enhancing lesions or new/enlarging T2 lesions), while non-active (stable) disease shows no relapses and no new MRI lesions over a defined surveillance period. 1

Core Definitions

Active Disease is characterized by:

  • Clinical activity: One or more relapses within the past 12 months
  • MRI activity: Gadolinium-enhancing lesions (indicating blood-brain barrier breakdown) OR new/enlarging T2 lesions on surveillance imaging
  • Either criterion alone is sufficient to classify disease as active 1

Non-Active (Stable) Disease requires:

  • No clinical relapses in the previous year
  • No new lesions on MRI (no gadolinium enhancement and no new T2 lesions)
  • Both criteria must be met simultaneously 1, 2

Why This Distinction Matters Clinically

MRI detects disease activity 5-10 times more frequently than clinical relapses, meaning most inflammatory lesions are clinically silent 1. This makes the active/non-active distinction heavily dependent on imaging surveillance rather than symptoms alone.

In real-world practice, MRI identifies 59.1% of active cases independently, while relapses alone identify only 12.7%, and both together account for 28.3% 2. This underscores why patients classified as "non-active" based on clinical assessment alone may actually have ongoing disease activity.

Critical Pitfall in Non-Active Classification

A major concern: In the EXPAND trial, 53% of patients classified as "non-active" at baseline actually demonstrated disease activity during follow-up, with 74.1% of this activity detected by MRI, only 8.4% by relapse, and 17.5% by both 2. This reveals that "non-active" is a snapshot classification that doesn't guarantee continued stability.

Surveillance Implications

For stable patients on established disease-modifying therapy:

  • Routine follow-up brain MRI is recommended yearly 1
  • Gadolinium contrast is NOT routinely required for surveillance in stable patients unless showing disease activity is needed to change treatment 1
  • New or enlarging T2 lesions alone indicate inflammatory activity even without gadolinium enhancement 1

For patients with active disease:

  • Gadolinium-enhanced MRI is recommended to detect active inflammation and guide treatment escalation 1
  • Contrast is particularly valuable when treatment decisions depend on demonstrating active lesions 1

The Real-World Gap

In clinical practice, only 58.7% of non-active patients received an MRI in the past year compared to 87.7% of active patients 2. This is problematic because most disease activity is detected via MRI, meaning non-active patients may be under-monitored and miss opportunities for treatment adjustment before disability accumulates.

The key takeaway: "Non-active" disease requires both clinical AND radiological stability, but this classification is time-dependent and requires regular MRI surveillance to maintain accuracy, as subclinical activity is common and prognostically important.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.